Compensatory evolution of Pseudomonas aeruginosa's slow growth phenotype suggests mechanisms of adaptation in cystic fibrosis

Nat Commun. 2021 May 27;12(1):3186. doi: 10.1038/s41467-021-23451-y.

Abstract

Long-term infection of the airways of cystic fibrosis patients with Pseudomonas aeruginosa is often accompanied by a reduction in bacterial growth rate. This reduction has been hypothesised to increase within-patient fitness and overall persistence of the pathogen. Here, we apply adaptive laboratory evolution to revert the slow growth phenotype of P. aeruginosa clinical strains back to a high growth rate. We identify several evolutionary trajectories and mechanisms leading to fast growth caused by transcriptional and mutational changes, which depend on the stage of adaptation of the strain. Return to high growth rate increases antibiotic susceptibility, which is only partially dependent on reversion of mutations or changes in the transcriptional profile of genes known to be linked to antibiotic resistance. We propose that similar mechanisms and evolutionary trajectories, in reverse direction, may be involved in pathogen adaptation and the establishment of chronic infections in the antibiotic-treated airways of cystic fibrosis patients.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adaptation, Physiological / drug effects
  • Adaptation, Physiological / genetics
  • Anti-Bacterial Agents / pharmacology*
  • Anti-Bacterial Agents / therapeutic use
  • Bacterial Proteins / genetics
  • Cell Proliferation / drug effects
  • Cell Proliferation / genetics
  • Cystic Fibrosis / complications*
  • Cystic Fibrosis / drug therapy
  • Cystic Fibrosis / immunology
  • Cystic Fibrosis / microbiology
  • DNA Mutational Analysis
  • DNA, Bacterial / genetics
  • DNA, Bacterial / isolation & purification
  • Directed Molecular Evolution
  • Drug Resistance, Microbial / drug effects
  • Drug Resistance, Microbial / genetics*
  • Evolution, Molecular*
  • Gene Expression Regulation, Bacterial
  • Genetic Fitness / drug effects
  • Genome, Bacterial
  • Humans
  • Lung / immunology
  • Lung / microbiology
  • Microbial Sensitivity Tests
  • Mutation
  • Phenotype
  • Pseudomonas Infections / drug therapy*
  • Pseudomonas Infections / immunology
  • Pseudomonas Infections / microbiology
  • Pseudomonas aeruginosa / drug effects
  • Pseudomonas aeruginosa / genetics*
  • Pseudomonas aeruginosa / isolation & purification
  • Sputum / microbiology

Substances

  • Anti-Bacterial Agents
  • Bacterial Proteins
  • DNA, Bacterial